Abstract
A 68-year-old man is being treated with cisplatin-pemetrexed in the first line for bone metastatic lung adenocarcinoma. There is partial response and very good tolerance with no grade 3–4 toxicities. After six cycles of doublet therapy, the patient follows on pemetrexed maintenance. Six months later, he develops a hot and itchy rash with …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
